DK2694049T3 - Tapentadol til forebyggelse af kronificering af smerte - Google Patents

Tapentadol til forebyggelse af kronificering af smerte Download PDF

Info

Publication number
DK2694049T3
DK2694049T3 DK12718064.4T DK12718064T DK2694049T3 DK 2694049 T3 DK2694049 T3 DK 2694049T3 DK 12718064 T DK12718064 T DK 12718064T DK 2694049 T3 DK2694049 T3 DK 2694049T3
Authority
DK
Denmark
Prior art keywords
cronification
tapentadol
pain
prevention
Prior art date
Application number
DK12718064.4T
Other languages
English (en)
Inventor
Klaus Schiene
Ilona Steigerwald
Michel Hamon
Johannes Schneider
Ulrich Jahnel
Thomas Tzschentke
Silvia Reinartz
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46025592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2694049(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Application granted granted Critical
Publication of DK2694049T3 publication Critical patent/DK2694049T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK12718064.4T 2011-04-05 2012-04-03 Tapentadol til forebyggelse af kronificering af smerte DK2694049T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11002811 2011-04-05
EP11003508 2011-04-29
PCT/EP2012/001472 WO2012136349A1 (en) 2011-04-05 2012-04-03 Tapentadol for preventing chronification of pain

Publications (1)

Publication Number Publication Date
DK2694049T3 true DK2694049T3 (da) 2019-01-02

Family

ID=46025592

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12718064.4T DK2694049T3 (da) 2011-04-05 2012-04-03 Tapentadol til forebyggelse af kronificering af smerte

Country Status (13)

Country Link
US (3) US20120309841A1 (da)
EP (2) EP2694049B1 (da)
JP (3) JP2014510759A (da)
CY (1) CY1121012T1 (da)
DK (1) DK2694049T3 (da)
ES (1) ES2703282T3 (da)
HR (1) HRP20181998T1 (da)
LT (1) LT2694049T (da)
PL (1) PL2694049T3 (da)
PT (1) PT2694049T (da)
RS (1) RS58064B1 (da)
SI (1) SI2694049T1 (da)
WO (1) WO2012136349A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510759A (ja) 2011-04-05 2014-05-01 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 疼痛の慢性化を予防するためのタペンタドール
JP6014655B2 (ja) 2011-04-29 2016-10-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング うつ病および不安を予防し治療するためのタペンタドール
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
AU2021201351B1 (en) * 2020-11-10 2022-04-21 Grünenthal GmbH Dosage form providing prolonged release of a salt of Tapentadol with L-(+)-tartaric acid

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20070054843A1 (en) 2005-08-26 2007-03-08 Yeomans David C Methods for treatment of headaches by administration of oxytocin
WO2007088473A2 (en) 2006-02-03 2007-08-09 Neurocure Ltd Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
RU2465263C2 (ru) * 2006-04-28 2012-10-27 Грюненталь Гмбх Фармацевтическая комбинация, включающая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и нестероидный противовоспалительный препарат
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
MX2010005680A (es) * 2007-11-23 2010-12-21 Protect Pharmaceutical Corp Composiciones de tapentadol.
US20100297181A1 (en) 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US20100227921A1 (en) 2009-03-03 2010-09-09 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
MX2011011442A (es) 2009-04-30 2011-11-18 Gruenenthal Gmbh Uso de compuestos de 1-fenil-3-dimetilaminopropano para tratar dolor reumatoide.
FR2970261B1 (fr) 2011-01-10 2013-05-03 IFP Energies Nouvelles Procede d'hydrotraitement de charges lourdes d'hydrocarbures avec des reacteurs permutables incluant au moins une etape de permutation progressive
JP2014510759A (ja) * 2011-04-05 2014-05-01 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 疼痛の慢性化を予防するためのタペンタドール

Also Published As

Publication number Publication date
EP3449917A3 (en) 2019-06-05
PT2694049T (pt) 2019-02-06
WO2012136349A1 (en) 2012-10-11
US20160354324A1 (en) 2016-12-08
EP2694049A1 (en) 2014-02-12
JP2019142932A (ja) 2019-08-29
HRP20181998T1 (hr) 2019-01-25
SI2694049T1 (sl) 2019-01-31
EP2694049B1 (en) 2018-10-31
EP3449917A2 (en) 2019-03-06
ES2703282T3 (es) 2019-03-07
LT2694049T (lt) 2018-12-27
PL2694049T3 (pl) 2019-07-31
CY1121012T1 (el) 2019-12-11
US10398657B2 (en) 2019-09-03
JP2018048122A (ja) 2018-03-29
US20200009083A1 (en) 2020-01-09
US10813891B2 (en) 2020-10-27
JP2014510759A (ja) 2014-05-01
RS58064B1 (sr) 2019-02-28
JP6840057B2 (ja) 2021-03-10
US20120309841A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK3454346T3 (da) Anordning til cylotronfremstilling af technetium-99m
DK2768479T3 (da) Hjælpestoffer til nikotin-indeholdende terapeutiske sammensætninger
DK2701733T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
CO6960555A2 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
DK2704703T3 (da) Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf
DK3442228T3 (da) Fremgangsmåde til billedafkodning
DK2785801T4 (da) Fremgangsmåde til formindskelse af isdannelse på et underlag
CO6900117A2 (es) Formulaciones peptídicas de liberación controlada
BR112013025299A2 (pt) conjunto de ancoragem
DK3581199T3 (da) Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis
DK2734212T3 (da) Sammensætninger omfattende diclofenac til behandling af postoperativ smerte
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK2701707T3 (da) Fremgangsmåde til behandling af dyskinesi
DK2788353T3 (da) Bur-aminligander til metallo-radiofarmaceutika
HRP20181998T1 (hr) Tapentadol za sprječavanje kronifikacije boli
DK2920151T3 (da) Fremgangsmåde til fremstilling af carboxamider
DK3202769T3 (da) Fremgangsmåde til oprensning af phosphaplatinforbindelser
DK2655360T3 (da) Fremgangsmåde til fremstilling af n-sulfonylsubstituerede oxindoler
DK2522421T3 (da) Fremgangsmåde til opnåelse af mikrokapsler
DK2745928T3 (da) Fremgangsmåde til emulsionsfremstilling
DK2844623T3 (da) Fremgangsmåder til fremstilling af perlitholdige byggematerialer
DK2793913T3 (da) Doseringsskema til apolipoproteinformuleringer
DK2739565T3 (da) Fremgangsmåde til fremstilling af partikelklynger
DK2694094T3 (da) FREMGANGSMÅDE TIL BEHANDLING AF IFN-alpha-RELATEREDE TILSTANDE